Gufic Biosciences reported a total revenue of ₹252.1 crore for the quarter ended March 31, 2026 (Q4 FY26), marking an increase from ₹205 crore in Q4 FY25. The company achieved a Profit After Tax (PAT) of ₹20.6 crore for the quarter, compared to ₹8 crore in the corresponding period of the previous year. For the full financial year FY26, the company recorded a total revenue of ₹940.5 crore and a PAT of ₹63.2 crore.

Financial Performance

The company's EBITDA for Q4 FY26 stood at ₹45.9 crore, with an EBITDA margin of 18.22%, up from 12.99% in Q4 FY25. The full-year EBITDA for FY26 was ₹152.9 crore. The Indore facility, which commenced production in October 2024, achieved 30% capacity utilization in FY26. The management indicated that at peak utilization (75%+), the Indore facility alone can generate approximately ₹675–700 crore of revenue from domestic and export markets.

The table below summarises the company's key financial metrics across recent quarters and full years:

Operational Updates

The Indore facility is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards. It houses capabilities for 5 million lyophilized vials per month, 6 million liquid vials per month, and 10 million ampoules per month. The company has received 203 State FDA approvals to date. In Q4 FY26, the company executed GLP-1 validation batches for a big pharma client and commenced the migration of CMO clients from the Navsari Unit-2 to Indore.

International Business

Gufic Biosciences is shifting its international business model from a distributor-led approach to an IP-owned, complex-injectable-led market access model. Gufic Ireland secured its first Marketing Authorization in the EU, providing direct access to EU markets. The company filed 2 products in 18 EU countries in the current quarter. Additionally, 24 key product and facility approvals were secured across South Africa, Colombia, Portugal, Myanmar, Sri Lanka, Cambodia, Thailand, and Lithuania in H1.

Gufic Biosciences Limited reported a consolidated net profit of ₹642.15 crore for the financial year ended March 31, 2026, a decrease from ₹696.50 crore in the previous year. Revenue from operations for the year rose to ₹9,440.07 crore, compared to ₹8,198.06 crore in FY25. The Board of Directors, meeting on May 29, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend of 10%, or Re. 0.10 per equity share having a face value of Re. 1 each, subject to shareholder approval at the ensuing Annual General Meeting.

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹21.90 crore, a significant increase from ₹7.72 crore in the same quarter of the previous year. Quarterly revenue stood at ₹251.82 crore, up from ₹205.02 crore in Q4FY25. The Statutory Auditors, M/s. Mittal Agarwal & Co., issued an unmodified opinion on the financial results.

Key Financial Highlights

The Board also approved the re-appointment of M/s. Poddar & Co., Cost Accountants, for FY27 and appointed Mrs. Saroj R. Kirdolia as the Internal Auditor effective from the financial year 2026-27. Additionally, the company sanctioned a further investment of ₹5.75 crore in Saraswat Co-operative Bank Limited by subscribing to 57,50,800 equity shares at a face value of ₹10 each.

The company amended its Code of Conduct for Directors and Senior Management Personnel to align with the Companies Act, 2013, and Listing Regulations. The meeting was held in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.